Ortataxel is under clinical development by Spectrum Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ortataxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ortataxel (BAY 59-8862, IDN-5109) is under development for the treatment of taxane-refractory solid tumors. It is a new chemical entity (NCE). The drug candidate is administered through intravenous and oral routes. It is a semi-synthetic taxane acts by targeting tubulin protein. It was also under development for the treatment of advanced renal cell carcinoma, recurrent glioblastoma, metastatic breast cancer, non-small cell lung carcinoma (NSCLC) and non-Hodgkin's lymphoma.
Spectrum Pharmaceuticals overview
Spectrum Pharmaceuticals (Spectrum) is a biopharma company that acquires, develops, and commercializes novel drug candidates for treatment of cancer. The company’s pipeline products include ROLONTIS, for treatment of chemotherapy-induced neutropenia helps to reduce the frequency of multiplication of tumors. This product is in phase 3 trails.; Poziotinib, an irreversible tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) tumors with various mutations. This product is in phase 2 trials and lead candidate for the organization. The company has R&D facilities in, Massachusetts and California, the US. The company operates in the US, Europe, Japan, and other countries. Spectrum is headquartered in Henderson, Nevada, the US.
For a complete picture of Ortataxel’s drug-specific PTSR and LoA scores, buy the report here.